Heart Failure

T. L. De Backer; A. A. Mangoni

doi:10.1007/978-3-031-28061-0_19

Heart Failure

T. L. De Backer, A. A. Mangoni

College of Medicine and Public Health

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Older patients are the fastest growing and the most heterogeneous population. As many diseases occur more frequently with advancing age, so do cardiovascular diseases as well, and “cardiogeriatrics” has become an established term/specialty. Heart failure (HF) specifically is a highly prevalent disease in the older population. Most established standard treatments are effective in this group. However, the presence of comorbidities, polypharmacy, and frailty makes the management of HF in older patients more complex, and the benefit-risk of each treatment must be carefully weighed by a multidisciplinary team and shared with the patient and/or his/her relatives as part of a shared decision-making and a personalised care plan. We should keep in mind that we treat people, not diseases.

Original language	English
Title of host publication	Optimizing Pharmacotherapy in Older Patients
Subtitle of host publication	An Interdisciplinary Approach
Editors	Antonio Cherubini, Arduino A. Mangoni, Denis O’Mahony, Mirko Petrovic
Place of Publication	Cham, Switzerland
Publisher	Springer Nature
Chapter	19
Pages	239-267
Number of pages	29
ISBN (Electronic)	978-3-031-28061-0
ISBN (Print)	978-3-031-28060-3
DOIs	https://doi.org/10.1007/978-3-031-28061-0_19
Publication status	Published - 2023

Publication series

Name	Practical Issues in Geriatrics
Volume	Part F12
ISSN (Print)	2509-6060
ISSN (Electronic)	2509-6079

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adverse drug events
Benefit-risk
Cardiogeriatrics
Cardiovascular diseases (CVD)
Comorbidities
Comprehensive geriatric assessment
Frailty
Heart failure (HF)
Heart failure with mildly reduced or midrange ejection fraction (HFmrEF)
Heart failure with preserved ejection fraction (HFpEF)
Heart failure with reduced ejection fraction (HFrEF)
Multidisciplinary
New York Heart Association (NYHA) class
Older persons
Personalised care
Polypharmacy
Underprescription

Access to Document

10.1007/978-3-031-28061-0_19Licence: In Copyright

https://rdcu.be/djc2uLicence: In Copyright

Cite this

@inbook{ff1964a6ddcd4c7cbd615c88dd459c56,

title = "Heart Failure",

abstract = "Older patients are the fastest growing and the most heterogeneous population. As many diseases occur more frequently with advancing age, so do cardiovascular diseases as well, and “cardiogeriatrics” has become an established term/specialty. Heart failure (HF) specifically is a highly prevalent disease in the older population. Most established standard treatments are effective in this group. However, the presence of comorbidities, polypharmacy, and frailty makes the management of HF in older patients more complex, and the benefit-risk of each treatment must be carefully weighed by a multidisciplinary team and shared with the patient and/or his/her relatives as part of a shared decision-making and a personalised care plan. We should keep in mind that we treat people, not diseases.",

keywords = "Adverse drug events, Benefit-risk, Cardiogeriatrics, Cardiovascular diseases (CVD), Comorbidities, Comprehensive geriatric assessment, Frailty, Heart failure (HF), Heart failure with mildly reduced or midrange ejection fraction (HFmrEF), Heart failure with preserved ejection fraction (HFpEF), Heart failure with reduced ejection fraction (HFrEF), Multidisciplinary, New York Heart Association (NYHA) class, Older persons, Personalised care, Polypharmacy, Underprescription",

author = "{De Backer}, {T. L.} and Mangoni, {A. A.}",

year = "2023",

doi = "10.1007/978-3-031-28061-0_19",

language = "English",

isbn = "978-3-031-28060-3",

series = "Practical Issues in Geriatrics",

publisher = "Springer Nature",

pages = "239--267",

editor = "Antonio Cherubini and Mangoni, {Arduino A.} and Denis O{\textquoteright}Mahony and Mirko Petrovic",

booktitle = "Optimizing Pharmacotherapy in Older Patients",

address = "Germany",

}

Heart Failure. / De Backer, T. L.; Mangoni, A. A.
Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach. ed. / Antonio Cherubini; Arduino A. Mangoni; Denis O’Mahony; Mirko Petrovic. Cham, Switzerland: Springer Nature, 2023. p. 239-267 (Practical Issues in Geriatrics; Vol. Part F12).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Heart Failure

AU - De Backer, T. L.

AU - Mangoni, A. A.

PY - 2023

Y1 - 2023

N2 - Older patients are the fastest growing and the most heterogeneous population. As many diseases occur more frequently with advancing age, so do cardiovascular diseases as well, and “cardiogeriatrics” has become an established term/specialty. Heart failure (HF) specifically is a highly prevalent disease in the older population. Most established standard treatments are effective in this group. However, the presence of comorbidities, polypharmacy, and frailty makes the management of HF in older patients more complex, and the benefit-risk of each treatment must be carefully weighed by a multidisciplinary team and shared with the patient and/or his/her relatives as part of a shared decision-making and a personalised care plan. We should keep in mind that we treat people, not diseases.

AB - Older patients are the fastest growing and the most heterogeneous population. As many diseases occur more frequently with advancing age, so do cardiovascular diseases as well, and “cardiogeriatrics” has become an established term/specialty. Heart failure (HF) specifically is a highly prevalent disease in the older population. Most established standard treatments are effective in this group. However, the presence of comorbidities, polypharmacy, and frailty makes the management of HF in older patients more complex, and the benefit-risk of each treatment must be carefully weighed by a multidisciplinary team and shared with the patient and/or his/her relatives as part of a shared decision-making and a personalised care plan. We should keep in mind that we treat people, not diseases.

KW - Adverse drug events

KW - Benefit-risk

KW - Cardiogeriatrics

KW - Cardiovascular diseases (CVD)

KW - Comorbidities

KW - Comprehensive geriatric assessment

KW - Frailty

KW - Heart failure (HF)

KW - Heart failure with mildly reduced or midrange ejection fraction (HFmrEF)

KW - Heart failure with preserved ejection fraction (HFpEF)

KW - Heart failure with reduced ejection fraction (HFrEF)

KW - Multidisciplinary

KW - New York Heart Association (NYHA) class

KW - Older persons

KW - Personalised care

KW - Polypharmacy

KW - Underprescription

UR - http://www.scopus.com/inward/record.url?scp=85163685747&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-28061-0_19

DO - 10.1007/978-3-031-28061-0_19

M3 - Chapter

AN - SCOPUS:85163685747

SN - 978-3-031-28060-3

T3 - Practical Issues in Geriatrics

SP - 239

EP - 267

BT - Optimizing Pharmacotherapy in Older Patients

A2 - Cherubini, Antonio

A2 - Mangoni, Arduino A.

A2 - O’Mahony, Denis

A2 - Petrovic, Mirko

PB - Springer Nature

CY - Cham, Switzerland

ER -

Heart Failure

Abstract

Publication series

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this